AMEX · MLSS

Milestone Scientific, Inc.

$0.40 +$0.01 (+3.13%) 1D After hours

Key Metrics

$34.51M
Market cap
29.89×
P/E · TTM
Revenue · TTM
$1.15M
Net income
EPS · TTM $0.01
Dividend yield
Free cash flow
Beta · 1Y 1.32
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 23
    From its May 7 high, the share price fell 36%.

    Peak close $0.47 on May 7; trough close $0.30 on Jun 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -36%
  • May 7
    The stock moved +16.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7
  • Mar 23
    The stock moved +16.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 23

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$34.51M
Enterprise value
Shares outstanding88.4M
52-wk range$0.22 – $0.68
Avg volume · 20D329.0K
Net cash
Book value / share$0.03
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeAMEX
About Milestone Scientific, Inc.
IPO dateNov 3, 1995
Employees15

Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E29.89
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №$0.09

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 28.4% · —

Financial Health

Current ratio1.51
Quick ratio0.79
Debt / equity
Debt / EBITDA
Net cash
Working capital$2.50M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

$0.09 vs $0.40
Trades 4.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings